Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ — Keymed Biosciences Inc. (“Keymed”, 02162.HK) announced impressive interim results for 2025, marked by…
